68 results about "Mitoxantrone" patented technology

Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R* H, phenyl, alkyl with 1-6 carbon atoms.

This invention pertains to liposomal formulations of mitoxantrone and methods for their manufacture and use. The compositions of the present invention include liposomal formulations of mitoxantrone in which the liposome contains any of a variety of neutral or charged liposome-forming materials in addition to a compound that is thought to bind mitoxantrone, such as cardiolipin. The liposomal compositions can be used advantageously in conjunction with secondary therapeutic agents other than mitoxantrone, including antineoplastic, antifungal, antibiotic among other active agents. Methods are provided in which a therapeutically effective amount of the formulation is administered to a mammal, such as a human.

The invention belongs to the field of new auxiliary materials and new dosage forms of medicine preparations and relates to a chemotherapeutic drug-photosensitizer co-assembled nanoparticles and construction thereof. A chemotherapeutic drug is an anthracycline chemotherapeutic drug selected from mitoxantrone, doxorubicin or epirubicin; a photosensitizer is a porphyrin photosensitizer selected fromchlorine e6, hematoporphyrin monomethyl ether or a chlorophyll derivative, wherein the molar ratio of the chemotherapeutic drug to the photosensitizer is 3:1-1:3. A certain quantity of the chemotherapeutic drug and the photosensitizer or a mixture of the chemotherapeutic drug, the photosensitizer and PEG is dissolved in a proper quantity of organic solvent, and the solution is slowly dropwise added to water while stirring to form uniform nanoparticles spontaneously. The preparation process is simple, enlarged production is easy, particle size is small and uniform, and the nanoparticles can beenriched at tumor parts through a reinforced permeation retention effect; the nanoparticles have ultrahigh drug loading capacity and can reduce related toxicity of auxiliary materials; and surface modification is easy, and the circulation time of the nanoparticles in blood can be prolonged by PEG modification.

The subject invention provides a method of treating a subject afflicted with a form of multiple sclerosis comprising periodically administering to the subject an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of the form of multiple sclerosis in the subject so as to thereby treat the subject. The subject invention also provides a package comprising glatiramer acetate, mitoxantrone and instructions for use of the together to alleviate a symptom of a form of multiple sclerosis in a subject. Additionally, the subject invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of mitoxantrone, wherein the amounts when taken together are effective to alleviate a symptom of a form of multiple sclerosis in a subject. The subject invention further provides a pharmaceutical combination comprising separate dosage forms of an amount of glatiramer acetate and an amount of mitoxantrone, which combination is useful to alleviate a symptom of a form of multiple sclerosis in a subject.

The invention discloses a biological self-assembly nanometer crystal injection agent composition with a lympha targeted function and an administration mode for targeting a lymphatic system by using a biological self-assembly nanometer crystal injection agent. A recipe composition is prepared from 0.05 to 5 percent of mitoxantrone and mitoxantrone salt, 0.1 to 10 percent of osmotic pressure regulating agents, 0.001 to 0.1 percent of buffer agents, 0.01 to 0.1 percent of antioxidants, 0.05 to 1 percent of adsorbents and 0 to 20 percent of filling agents. The administration mode is interstitial injection; after the passive lymphatic system targeting, the lymph gland can generate the macroscopic blue color. The problems of poor in vitro and vivo physical and chemical property, poor storage stability, preparation flow process complexity and high cost of the micro particle preparation with the lympha targeted function are solved.

The invention relates to the field of anti-tumor, and discloses a purpose of a mitoxantrone liposome preparation for preparation of medicine for treating a lymphoma, wherein the lymphoma is preferablya non-hodgkin lymphoma, is further preferably an invasive non-hodgkin lymphoma, is more further preferably a recurrent and refractory invasive lymphoma, and is more further preferably a diffuse largeB cell lymphoma or a peripheral T-cell lymphoma. The mitoxantrone liposome preparation is singly used, and is not applied in a way of being combined with other anti-tumor medicine.

Novel lactones of polysaccharide carboxylic acids, and methods for the preparation of a variety of conjugates therefrom, as well as the novel conjugates, are provided. Conjugates include metallo-coordinated cisplatin (and carboplatin), as well as conjugates of ellipticinium, aminoglutethimide, mitoxantrone, mitoguazone, cis 3-hexen-1-ol, and other nucleophilic biologically effective agents. Also provided are conjugates via a coupling agent of biologically effective agents, such as Vitamin E, DTPA, TAXOL and TAXOTERE.

A group of new compounds, N-(all-trans-Retinoyl)-L-cysteic acid, N-(13-cis-Retinoyl)-L-cysteic acid, N-(all-trans-Retinoyl)-L-cysteinesulfinic acid, N-(13-cis-Retinoyl)-L-cysteinesulfinic acid, N-(all-trans-Retinoyl)-L-homocysteic acid, N-(13-cis-Retinoyl)-L-homocysteic acid, and sodium salts of these compounds, including sodium salts of their esters and amides, is shown to exhibit therapeutic effects per se, and which compounds in combination with cytotoxic compounds, such as docetaxel, paclitaxel, doxorubicin and mitoxantrone, exhibit a synergistic effect. These compounds make it possible to manufacture new formulations of poorly soluble pharmaceutical compounds, and the present invention discloses a process of manufacturing water-soluble formulations of such compounds, exemplified by docetaxel, and paclitaxel, exhibiting enhanced pharmacological activity, and formulations of water-soluble pharmaceuticals exemplified by doxorubicin and mitoxantrone, exhibiting improved therapeutic efficacy.

The invention relates to a temperature-controlled sustained-release injection containing an anti-cancer drug, which consists of the anti-cancer drug and an amphiphilic block copolymer hydrogel and has the temperature-sensitive gelatinization feature, the temperature-controlled sustained-release injection is flowable liquid in the environment that is lower than the body temperature and can be automatically converted to the water-insoluble gel that can not flow and be biodegradable for absorption in an endotherm, thus allowing the drug to have the local sustained release in a tumor and maintain the effective drug concentration for a plurality of weeks to a plurality of months; the temperature-controlled sustained-release injection can be injected in the tumor or the tumor periphery or be arranged in the postoperative tumor cavity, thus significantly reducing the systemic reaction of the drug, strengthening the treatment effects of chemotherapy, radiotherapy and other non-surgical therapies, and being used for the treatment of the tumors in different stages. The anti-cancer drug can be vincristine, vinorelbine, navelbine, vindesine, vinleurosine, vinrosidine, cephalotaxine, bleomycin, daunomycin, aclarubicin, epirubicin, idarubicin, pirarubicin, valrubicin, mitomycin C, actinomycin D, losoxantrone, mitoxantrone, mitozolomide, temozolomide and so on.

Conjugates of transferrin, albumin and polyethylence glycol consisting of native or thiolated transferrin or albumin or of polyethylene glycol (MW between approximately 5,000 and 20,0000) with at least one HS-, HO- or H2N group and cytostatic compounds derived through maleinimide or N-hydroxysuccinimide ester compounds, such as doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxandrone, chloroambucil, melphalan, 5-fluorouracyl, 5'-desoxy-5-fluorouridine, thioguanine, methotrexate, paclitaxel, docetaxel, topotecan, 9-aminocamptothecin, etoposide, teniposide, mitopodoside, vinblastine, vincristine, vindesine, vinorelbine or a compound of general formula A, B, C or D, where n=0-6, X=-NH2, -OH, -COOH, -O-CO-R-COR*, -NH-CO-R-COR*, where R is an aliphatic carbon chain with 1-6 carbon atoms or a substituted or unsubstituted phenylene group and R*H, phenyl, alkyl with 1-6 carbon atoms.

The present invention describes the use of radio-labeled antitumor drugs in the treatment of solid tumors by the method of administering a radio-labelled anticancer drug to a patient and imaging at least a part of the patient using Positron Emission Tomography imaging. The method is used to monitor delivery of antitumor drugs to tumors and may be used to predict the effectiveness of therapy with a particular antitumor drug or combination of antitumor drugs, to assess the effectiveness of modulators of cellular accumulation, to individualize therapy and to evaluate the effectiveness of antitumor drugs with respect to particular cancers. Particularly preferred drugs are labeled taxanes, e.g., 11C-paclitaxel and 11C-docetaxel, labeled anthracyclines, e.g., 11C-doxorubicin and 11C-epirubicin, and other radio-labeled drug, e.g. 11C-topotecan and 11C-mitoxantrone. The invention further describes antitumor drugs labeled with the radioactive label 11C and methods of preparing radio-labeled drugs.

The invention relates to a method and a kit for detecting breast cancer resistance protein (BCRP) gene mutation related to treatment effect of molecular targeted anti-cancer medicines, in particular to a fluorescence quantitative polymerase chain reaction (PCR) detection method and a kit for detecting mutation in a BCRP genic mutation hotspot region, and application thereof. By the invention, the mutation of a specific BCRP gene locus is detected, the treatment effects of anti-tumor medicines such as mitoxantrone MX, adriamycin, daunorubicin, etoposide, topotecan, Irinotecan, CPT-11, cis-platinum, taxol, vinblastine and the like are predicted, and guidance is provided for clinical individualized medication schemes for patients suffering from tumors.